Novodex Pharma Private Limited
About Novodex Pharma Private Limited
Data last updated:
Novodex Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the consumer and professional services segment of the travel and hospitality sector. It was incorporated on 17 February 2012 and has been in existence for over 14 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U21001MH2012PTC227081. Its GSTIN is 27AAFCR7168G1Z1 (Maharashtra).
The company has an authorised share capital of ₹3 Cr and a paid-up capital of ₹1 Lakh. It was formerly known as Rupalheri Estates Private Limited. It is led by directors including Arjun Singh Dhanoa and Ajay Kumar Mehrotra.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Flat No 601A Rising Sun Chs Juhu Rd Juhu, Mumbai, Maharashtra, India – 400049.
As per the financials filed for FY 2020, the company reported a revenue of ₹6.13 Lakh, a decline of 89% compared to the previous year. For the same year it recorded a net loss of ₹20.53 Lakh (net margin -334.9%) and EBITDA of -₹20.53 Lakh (EBITDA margin -334.9%). Revenue has declined at a compounded annual rate (CAGR) of 61% over three years and 39% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Name history
Novodex Pharma has undergone 2 name changes throughout its history. The company was previously known as Rupalheri Estates Private Limited, and Novodex Pharma Private Limited. The current legal name is Novodex Pharma Private Limited.
| Company Name | Status |
|---|---|
| Novodex Pharma Private Limited | Current |
| Rupalheri Estates Private Limited | Previous |
CIN history
Novodex Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U21001MH2012PTC227081, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U21001MH2012PTC227081 | Current |
| U45200MH2012PTC227081 | Previous |
| U74999MH2012PTC227081 | Previous |
Contact details
Novodex Pharma Private Limited's registered office is in Mumbai, Maharashtra.
- Registered AddressFlat No 601A Rising Sun Chs Juhu Rd Juhu, Mumbai, Maharashtra, India – 400049
- IndustryTravel and Hospitality, Consumer Professional Services
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Novodex Pharma Private Limited
FY 2025 filings availableNovodex Pharma Private Limited reported revenue of ₹6.13 Lakh (down 89% YoY) for FY 2020.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 39% over five years, including a 89% fall in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | ₹6.13 Lakh | ||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹20.53 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹20.53 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -334.9% | ||||
| Net Profit Margin | -334.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Novodex Pharma Private Limited, buy the company report.
Board of directors of Novodex Pharma Private Limited
Novodex Pharma has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arjun Singh Dhanoa | Director | 29 May 2015 | 11 Years 5 Months | Current |
| Ajay Kumar Mehrotra | Director | 31 Aug 2020 | 6 Years 1 Months | Current |
| Jagdeep Dhanoa | Director | 05 Nov 2012 | 13 Years 11 Months | Current |
Legal cases
No court or tribunal cases involving Novodex Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Novodex Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Novodex Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAFCR7168G1Z1 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Novodex Pharma Private Limited, buy the company report.
Recent activity
Novodex Pharma Private Limited has 6 board changes on record since 2012: 3 appointments and 3 cessations. The latest: Ajay Kumar Mehrotra ceased to be Additional Director on 31 Dec 2020.
Frequently asked questions
Novodex Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in consumer professional services, within the travel and hospitality industry. It was incorporated on 17 February 2012 (14+ years old) and is registered under CIN U21001MH2012PTC227081.
Novodex Pharma has 3 current directors:
- Arjun Singh Dhanoa - Director
- Ajay Kumar Mehrotra - Director
- Jagdeep Dhanoa - Director
The latest financial statements of Novodex Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Novodex Pharma is 27AAFCR7168G1Z1, registered in Maharashtra.
The CIN (Corporate Identification Number) of Novodex Pharma is U21001MH2012PTC227081. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Novodex Pharma was incorporated on 17 February 2012, making it 14+ years old. It is registered with the Registrar of Companies, Mumbai.
Ajay Kumar Mehrotra ceased to be Additional Director on 31 Dec 2020. Ajay Kumar Mehrotra was appointed as Director on 31 Aug 2020. Ritu Rattan Bhatnagar ceased to be Director on 28 Aug 2017. Novodex Pharma has 6 board changes on record in total.
The registered office of Novodex Pharma is at Flat No 601A Rising Sun Chs Juhu Rd Juhu, Mumbai, Maharashtra, India – 400049.
Novodex Pharma operates in the travel and hospitality industry, in the consumer professional services segment.
The compliance status of Novodex Pharma is compliant as of 12 July 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
